Sonesitatug Vedotin not checked
AstraZeneca · AZD0901 · CMG901
FollowEvery change as it happens, and a Monday email
Trials
6 active
6 in total · 5 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
- How it’s given
- “Participants in the AZD0901 arm 2 will receive dose level 2 AZD0901 IV (Enrolment was closed)”In the company’s words, NCT06346392 on ClinicalTrials.gov
- Tested for
- Gastric Cancer (5 trials), Gastroesophageal Junction Cancer (3 trials), Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Adenocarcinoma
- Main trialPhase 3
- “The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.”In the company’s words, NCT06346392 on ClinicalTrials.gov
- Other names
- AZD0901 · CMG901
Other drugs for Gastric Cancer
- CAM2029Camurus AB · Phase 3
- Disitamab VedotinRemeGen · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
- M108FutureGen Biopharmaceutical (Beijing) Co., Ltd · Phase 3
- RilvegostomigAstraZeneca · Phase 3
Coming up3
- 9 Nov 2027Phase 2 trial completes · ClinicalTrials.gov
- 30 Nov 2027Phase 2 trial completes · ClinicalTrials.gov
- 16 Aug 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 31 May 2026 | AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | |
| Phase 3Recruiting | 16 Aug 2029 | Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 | |
| Phase 2Active, not recruiting | 14 Aug 2026 | A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2 | |
| Phase 2Recruiting | 17 Nov 2026 | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | |
| Phase 2Recruiting | 9 Nov 2027 | A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma | |
| Phase 2Recruiting | 30 Nov 2027 | Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026